Abstract
The concentration of magnesium in serum has been shown to fall to potentially dangerously low levels after several courses of treatment with cis-diamminedichloroplatinum II (cis-platin). The aims of this study were to examine the effects of magnesium supplementation on predicted outcome of treatment, rate of response to treatment and toxicity of treatment. Sixteen patients with testicular cancer were studied in detail over a 14 month period. One patient with an ovarian dysgerminoma was also included in the study. Eight patients were randomised to receive magnesium supplements both intravenous and oral; nine did not. The non-supplemented group showed significantly greater renal tubular damage as assessed by urine N-acetyl-B-D-glucosaminidase (NAG). There was a trend towards a reduction in treatment delays due to neutropenic episodes in the supplemented group, and serum magnesium concentrations remained significantly higher. Neither group showed differences in tumour growth rates or outcome. These results show that magnesium supplements are of considerable benefit and show no harmful effects in patients receiving cis-platin treatment. It is is suggested that magnesium supplements should be a routine part of the treatment regime, and that these should comprise both i.v. supplements during treatment and oral supplements between courses.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Willox, J., McAllister, E., Sangster, G. et al. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: A randomised trial. Br J Cancer 54, 19–23 (1986). https://doi.org/10.1038/bjc.1986.147
Issue Date:
DOI: https://doi.org/10.1038/bjc.1986.147
This article is cited by
-
A systematic review for prevention of cisplatin-induced nephrotoxicity using different hydration protocols and meta-analysis for magnesium hydrate supplementation
Clinical and Experimental Nephrology (2024)
-
Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score–matched analysis
Supportive Care in Cancer (2022)
-
Short hydration with 20Â mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study
International Journal of Clinical Oncology (2020)
-
Efficacy and safety of oral magnesium supplementation in reducing febrile neutropenia episodes in children with solid tumors treated with cisplatin-based chemotherapy: randomized clinical trial
Cancer Chemotherapy and Pharmacology (2020)
-
Influence of oral magnesium-containing supplement and antacid administration on hypomagnesemia induced by panitumumab
Cancer Chemotherapy and Pharmacology (2019)